Among patients with EGFR status, there were no significant differences between patients with mutated EGFR and those with EGFR wild‐type in terms of overall survival (p = 0.781), progression‐free survival (p = 0.712), disease control rate (p = 0.688), distant control rate (p = 0.629), lung cancer‐specific survival (p = 0.905), or local control rate (p = 0.317) (Figure 3). This evidence concerns the gene EGFR and lung carcinoma.